Newsroom – Category: Knowledge Transfer

Select year

Tuberculosis vaccine candidate enters phase-2-trial

July 10, 2015

In the clinical trial HIV-exposed newborn infants are vaccinated with VPM1002 more

A synthesis of science and industry

July 07, 2015

Vaxxilon is a start-up company founded by the Max Planck Society and the Swiss biotech firm Actelion, which aims to bring synthetic, polysaccharide-based vaccines to market. more

The vaccines company

June 29, 2015

The Max Planck Society and Actelion found the start-up Vaxxilon to bring carbohydrate-based vaccines to market more

IT incubator to commercialize research results of computer science in Saarbrücken

March 10, 2015

Social Media

Max Planck Research

MaxPlanckResearch 2/2024: Focus: Law creates Freedom

The focus of this issue takes up the theme of the Science Year 2024 “Freedom”. How do laws and rules create freedom? In Germany, the Federal Constitutional Court watches over this in the last instance. Whether and how the highest court can be protected from anti-freedom and anti-democratic attacks is one of our topics. It is also about how the freedom of people who are existentially threatened by climate change can be secured - even if it is the freedom to seek refuge in other countries. Finally, we shed light on the extent to which Germany has benefited from the freedom that the EU has created, particularly with the single market, and how freedom and prosperity can be secured in the future.

Newsroom – Category: Knowledge Transfer

Tuberculosis vaccine candidate enters phase-2-trial

A synthesis of science and industry

The vaccines company

IT incubator to commercialize research results of computer science in Saarbrücken

Notification Settings